
Formulary Search
You are here : Home > Formulary Search
A to Z of Drugs : O
Show Icon and Status Keys Hide Icon and Status Keys
Icon Key



Status Key
- Tablets
- Infusion
ASPH are the only Surrey Heartlands Trust commissioned to provide this.
- Intravitreal injection
- Not Specified
- Depot injection
- Subcutaneous injection (sc)
NHSE Specialist Centres - only commissioned from RSFT in Surrey Heartlands.
SASH - only for use under shared care arrangements with specialist centres.
- Injection
- Subcutaneous injection (sc)
Prevention of complications following pancreatic surgery
- Subcutaneous injection (sc)
ASPH are the only Surrey Heartlands Trust commissioned to provide this.
- Tablets
- Oro-dispersible tablets
- Tablets
Off-label use. On recommendation of palliative care team.
- Oro-dispersible tablets
- Tablets
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
- Tablets
For the prevention of recurrence in bipolar disorder.
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
For the prevention of recurrence in bipolar disorder.
Initiation by a SABP specilalist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube.
- Oro-dispersible tablets
- Tablets
For the reduction of distress at mealtimes in anorexia nervosa.
- Tablets
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube.
- Oro-dispersible tablets
- Tablets
- Oro-dispersible tablets
Off-label use. Primary care prescribing on request of specialist palliative care team.
- Subcutaneous injection (sc)
Off-label use. Primary care prescribing on request of specialist palliative care team.
Off-label use.
- Not Specified
- Injection
Off-label use.
- Tablets
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube.
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
- Depot injection
Olanzapine embonate - maintenance in schizophrenia.
Not suitable for administration under the locally commissioned service (LCS).
Note 3 hour monitoring after dose .
- Ear drops
- Tablets
- Soft mist inhaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Eye drops
Prescribe generically.
- Capsules
- Tablets
Licensed in mild ulcerative colitis
- Not Specified
- Not Specified
Treatment resistant psychosis.
- Capsules
- Capsules
- Tablets
- Oral suspension
- Oro-dispersible tablets
- Capsules
- Dispersible tablets
- Oral suspension
- Powder
- Tablets
- Intravenous infusion
- Intravenous infusion
- Intravenous infusion
- Intravenous infusion
- Injection
- Oral solution
- Tablets
- Oro-dispersible tablets
- Orodispersible films
- Oral solution
- Tablets
- Oro-dispersible tablets
- Orodispersible films
- Injection
- Injection
- Oral solution
- Oro-dispersible tablets
- Tablets
Off-label use. On recommendation of palliative care team
- Injection
- Oral solution
- Tablets
- Oro-dispersible tablets
- Orodispersible films
- Suppositories
- Tablets
- Orodispersible films
- Oral solution
- Oro-dispersible tablets
Orodispersible films are a more cost effective option than oral solution and orodispersible tablets.
- Capsules
- Not Specified
- Eye drops
- Oromucosal gel
Oncology request only. Primary Care prescribing may be appropriate in longer-term use and on request from oncology specialist team only. Ongoing use should be reviewed regularly to ensure that therapy is still required.
- Sachets (powder)
Dioraltye Natural
- Sachets (powder)
Dioralyte Blackcurrant
- Sachets (powder)
Dioarlyte relief blackcurrant
- Capsules
- Not Specified
- Device
This device has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.
- Oral solution
- Oral suspension
- Tablets
recommended for treatment of influenza in adults and children meeting the criteria set out in NICE TA 168 and for prophylaxis of influenza in adults and children meeting the criteria set out in NICE TA 158
- Liquid
Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian
- Liquid
Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian
- Liquid
Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian
- Liquid
Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian
- Tablets
- Oral suspension
- Tablets
- Eye drops (preservative free
- unit dose)
- Capsules
- Capsules (slow release)
- Tablets
- Tablets (slow release)
- Elixir
- Liquid
- Oral solution
- Oral suspension
- Patches
- Patches
- Modified release tablets
- Oral solution
- Tablets
- Intravesical
This drug has not yet been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to the APC.
- Capsules
- Oral solution
- Modified release tablets
- Injection
- Injection
- Capsules
- Oral solution
For patients unable to tolerate / poor response to morphine.
- Modified release tablets
For use in patients where morphine sulfate is not suitable / not tolerated.
Modified-release preparations to be prescribed by brand
- Not Specified
- Tablets
- Tablets
- Intramuscular injection (IM)
- Intravenous infusion
- Capsules
- Capsules